Literature DB >> 35702054

HSA-MnO2-131I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma.

Ziyu Yan1, Xuemei Zhang1, Yifan Liu2, Yiming Shen1, Ning Li1, Qiang Jia1, Yanhui Ji1, Peitao Zhang2, Li Zhao2, Zhaowei Meng1.   

Abstract

Purpose Compelling evidence suggests that nanoparticles (NPs) play a crucial role in cancer therapy. NPs templated with human serum albumin (HSA) has good retention in tumors. Manganese dioxide (MnO2) has been used to enhance the effect of radiotherapy. In this study, synthesized NPs using HSA-MnO2 labeled 131I to perform both imaging and therapy for anaplastic thyroid carcinoma (ATC). Method HSA-MnO2 was synthesized via HSA using a simple biomineralization method, and then labeled with Na131I by the chloramine T method. The cytotoxicity and biosafety of HSA-MnO2 were evaluated by the MTT test. The proliferation-inhibiting effect of HSA-MnO2-131I was evaluated in papillary thyroid cancer cell lines (K1, BCPAP, and KTC) and anaplastic thyroid carcinoma cell lines (Cal62, THJ16T, and ARO). For further translational application in medicine, we established a model of transplantable subcutaneously tumors in BALB\c-nu mice to assess the anti-tumor effect of HSA-MnO2-131I. The imaging effects of NPs were evaluated by MRI and SPECT/CT. Results The MTT test proved that the HSA-MnO2 had low toxicity. HSA-MnO2-131I significantly inhibited the proliferation of PTC and ATC cell lines. In addition, the results unveiled that HSA-MnO2-131I exhibited dual-modality MR/SPECT imaging for thyroid cancer visualization. In particular, HSA-MnO2-131I had an enhanced T1 signal in MR. Using SPECT/CT, we observed that HSA-MnO2-131I had good retention in tumor tissue, which was helpful for the diagnosis and treatment of tumor. In vivo assays indicated that the NPs led to a reduction in radioresistance in the tumor hypoxic microenvironment. Conclusion The nanomaterial had a simple synthesis method, good water solubility and biosafety, and good retention in tumor tissue. Hence, it could be used for SPECT/CT and MR dual mode imaging and therapy with radioiodine of tumor cells. The experimental results provided a feasible solution for combining radiotherapy and dual-model imaging by NPs for cancer diagnosis and treatment.

Entities:  

Keywords:  combination therapy; nanomaterials; proliferation; radioiodine

Mesh:

Substances:

Year:  2022        PMID: 35702054      PMCID: PMC9208040          DOI: 10.1177/15330338221106557

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  29 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

Review 2.  Toward a molecular understanding of nanoparticle-protein interactions.

Authors:  Lennart Treuel; Gerd Ulrich Nienhaus
Journal:  Biophys Rev       Date:  2012-03-15

3.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.

Authors:  D M Aebersold; P Burri; K T Beer; J Laissue; V Djonov; R H Greiner; G L Semenza
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 4.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

5.  [Analysis of incidence and mortality of thyroid cancer in China, 2010].

Authors:  Lei Yang; Rongshou Zheng; Ning Wang; Siwei Zhang; Wanqing Chen
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2014-08

6.  Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure.

Authors:  José Willegaignon; Marcelo Sapienza; Carla Ono; Tomoco Watanabe; Maria Inês Guimarães; Ricardo Gutterres; Maria Helena Marechal; Carlos Buchpiguel
Journal:  Clin Nucl Med       Date:  2011-06       Impact factor: 7.794

7.  Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.

Authors:  Wei Li; Zhongyun Liu; Chengxia Li; Ning Li; Lei Fang; Jin Chang; Jian Tan
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-16       Impact factor: 4.553

Review 8.  Metal nanoclusters: Protein corona formation and implications for biological applications.

Authors:  Li Shang; Gerd Ulrich Nienhaus
Journal:  Int J Biochem Cell Biol       Date:  2015-09-25       Impact factor: 5.085

Review 9.  Managing side effects of radiotherapy in head and neck cancer.

Authors:  R L Mendes; C M Nutting; K J Harrington
Journal:  Hosp Med       Date:  2002-12

10.  [Analysis of Incidence and Mortality of Thyroid Cancer in China, 2013].

Authors:  L Yang; R S Zheng; N Wang; H M Zeng; Y N Yuan; S W Zhang; H C Li; S Liu; W Q Chen; J He
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2017-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.